Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $21.85 million
- Book Value:
- Revenue TTM:
- $24.64 million
- Operating Margin TTM:
- Gross Profit TTM:
- $15.76 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Equillium Inc had its IPO on 2018-10-11 under the ticker symbol EQ.
The company operates in the Healthcare sector and Biotechnology industry. Equillium Inc has a staff strength of 37 employees.
Shares of Equillium Inc opened at $0.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.8 - $0.82, and closed at $0.8.
This is a -0.51% slip from the previous day's closing price.
A total volume of 65,975 shares were traded at the close of the day’s session.
In the last one week, shares of Equillium Inc have increased by +0.75%.
Equillium Inc's Key Ratios
Equillium Inc has a market cap of $21.85 million, indicating a price to book ratio of 1.4883 and a price to sales ratio of 0.
In the last 12-months Equillium Inc’s revenue was $24.64 million with a gross profit of $15.76 million and an EBITDA of $-28731000. The EBITDA ratio measures Equillium Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Equillium Inc’s operating margin was -117.12% while its return on assets stood at -24.7% with a return of equity of -70.7%.
In Q1, Equillium Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Equillium Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Equillium Inc’s profitability.
Equillium Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1214. Its price to sales ratio in the trailing 12-months stood at 0.
Equillium Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $71.79 million
- Total Liabilities
- $32.02 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Equillium Inc ended 2023 with $71.79 million in total assets and $0 in total liabilities. Its intangible assets were valued at $71.79 million while shareholder equity stood at $29.27 million.
Equillium Inc ended 2023 with $0 in deferred long-term liabilities, $32.02 million in other current liabilities, 3000.00 in common stock, $-176345000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.50 million and cash and short-term investments were $61.99 million. The company’s total short-term debt was $6,118,000 while long-term debt stood at $1.84 million.
Equillium Inc’s total current assets stands at $70.22 million while long-term investments were $0 and short-term investments were $37.49 million. Its net receivables were $3.42 million compared to accounts payable of $5.69 million and inventory worth $0.
In 2023, Equillium Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Equillium Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Equillium Inc stock is currently trading at $0.8 per share. It touched a 52-week high of $3.2 and a 52-week low of $3.2. Analysts tracking the stock have a 12-month average target price of $4.67.
Its 50-day moving average was $0.81 and 200-day moving average was $0.87 The short ratio stood at 2.93 indicating a short percent outstanding of 0%.
Around 3188.8% of the company’s stock are held by insiders while 3030.1% are held by institutions.
Frequently Asked Questions About Equillium Inc
Similar Industry Stocks (Biotechnology)
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.